导管消融与药物治疗对心房颤动患者生活质量的影响:CABANA随机临床试验
CABANA随机临床试验纳入2204例症状性心房颤动患者,比较导管消融与药物治疗对生活质量的影响。12个月时,消融组AFEQT汇总评分优于药物组(86.4分 vs 80.9分,校正差值5.3分,95%CI 3.7-6.9,P<.001),MAFSI频率评分和严重程度评分也均优于药物组。
要点
- 12个月时消融组AFEQT评分86.4分 vs 药物组80.9分,校正差值5.3分(95%CI 3.7-6.9,P<.001)。
- 12个月时消融组MAFSI频率评分6.4分 vs 药物组8.1分,校正差值-1.7分(95%CI -2.3至-1.2,P<.001)。
- 12个月时消融组MAFSI严重程度评分5.0分 vs 药物组6.5分,校正差值-1.5分(95%CI -2.0至-1.1,P<.001)。
核心结论
- 在症状性心房颤动患者中,与药物治疗相比,导管消融在12个月时带来具有临床意义且显著的生活质量改善,这些发现有助于指导心房颤动管理决策。
研究设计与样本
- 开放标签随机临床试验,比较导管消融与药物治疗,纳入2204例症状性心房颤动患者(年龄>65岁,或≤65岁且至少1项卒中危险因素)。
- 患者于2009年11月至2016年4月从10个国家126个中心入组,随访于2017年12月结束。
- 消融组(n=1108)接受肺静脉隔离,研究者可酌情增加消融操作;药物组(n=1096)由研究者选择和管理标准节律和/或心率控制药物。
主要发现
- 2204例随机患者中位年龄68岁,男性1385例(63%),阵发性心房颤动946例(43%),持续性心房颤动1256例(57%),中位随访48.5个月,1968例(89%)完成试验。
- 12个月时消融组AFEQT汇总评分均值86.4分 vs 药物组80.9分,校正差值5.3分(95%CI 3.7-6.9,P<.001)。
- 12个月时消融组MAFSI频率评分均值6.4分 vs 药物组8.1分,校正差值-1.7分(95%CI -2.3至-1.2,P<.001)。
- 12个月时消融组MAFSI严重程度评分均值5.0分 vs 药物组6.5分,校正差值-1.5分(95%CI -2.0至-1.1,P<.001)。
关键数值与推荐
- AFEQT汇总评分范围0-100分,0分表示完全残疾,100分表示无残疾,患者层面临床重要差异≥5分。
- MAFSI频率评分范围0-40分,0分表示无症状,40分表示最严重症状,患者层面临床重要差异≤-1.6分。
- MAFSI严重程度评分范围0-30分,0分表示无症状,30分表示最严重症状,患者层面临床重要差异≤-1.3分。
临床怎么用
- 原文结论指出,这些发现有助于指导心房颤动管理决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Catheter ablation is more effective than drug therapy in restoring sinus rhythm in patients with atrial fibrillation (AF), but its incremental effect on long-term quality of life (QOL) is uncertain. OBJECTIVE: To determine whether catheter ablation is more beneficial than conventional drug therapy for improving QOL in patients with AF. DESIGN, SETTING, AND PARTICIPANTS: An open-label randomized clinical trial of catheter ablation vs drug therapy in 2204 symptomatic patients with AF older than 65 years or 65 years or younger with at least 1 risk factor for stroke. Patients were enrolled from November 2009 to April 2016 from 126 centers in 10 countries. Follow-up ended in December 2017. INTERVENTIONS: Pulmonary vein isolation, with additional ablation procedures at the discretion of the investigators, for the catheter ablation group (n = 1108) and standard rhythm and/or rate-control drugs selected and managed by investigators for the drug therapy group (n = 1096). MAIN OUTCOMES AND MEASURES: Prespecified co-primary QOL end points at 12 months, including the Atrial Fibrillation Effect on Quality of Life (AFEQT) summary score (range, 0-100; 0 indicates complete disability and 100 indicates no disability; patient-level clinically important difference, ≥5 points) and the Mayo AF-Specific Symptom Inventory (MAFSI) frequency score (range, 0-40; 0 indicates no symptoms and 40 indicates the most severe symptoms; patient-level clinically important difference, ≤-1.6 points) and severity score (range, 0-30; 0 indicates no symptoms and 30 indicates the most severe symptoms; patient-level clinically important difference, ≤-1.3 points). RESULTS: Among 2204 randomized patients (median age, 68 years; 1385 patients [63%] were men, 946 [43%] had paroxysmal AF, and 1256 [57%] had persistent AF), the median follow-up was 48.5 months, and 1968 (89%) completed the trial. The mean AFEQT summary score was more favorable in the catheter ablation group than the drug therapy group at 12 months (86.4 points vs 80.9 points) (adjusted difference, 5.3 points [95% CI, 3.7-6.9]; P < .001). The mean MAFSI frequency score was more favorable for the catheter ablation group than the drug therapy group at 12 months (6.4 points vs 8.1 points) (adjusted difference, -1.7 points [95% CI, -2.3 to -1.2]; P < .001) and the mean MAFSI severity score was more favorable for the catheter ablation group than the drug therapy group at 12 months (5.0 points vs 6.5 points) (adjusted difference, -1.5 points [95% CI, -2.0 to -1.1]; P < .001). CONCLUSIONS AND RELEVANCE: Among patients with symptomatic atrial fibrillation, catheter ablation, compared with medical therapy, led to clinically important and significant improvements in quality of life at 12 months. These findings can help guide decisions regarding management of atrial fibrillation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00911508.
引用
- Mark DB, Anstrom KJ, Sheng S, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019. PMID: 30874716. doi:10.1001/jama.2019.0692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。